MaxCyte Inc MXCT
News
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte Reports Second Quarter 2026 Financial Results
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
